MEI Pharma, Inc.
(NASDAQ : MEIP)

( )
MEIP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-1.83%19.292.0%$636.97m
SHPGShire PLC Sponsored ADR
1.03%172.170.4%$144.47m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.06%143.236.8%$139.89m
PRGOPerrigo Co. Plc
2.42%71.866.8%$99.72m
JAZZJazz Pharmaceuticals Plc
-2.24%155.272.2%$67.34m
ENDPEndo International Plc
-0.17%17.488.9%$62.01m
MNKMallinckrodt Plc
0.07%27.1821.1%$60.38m
ICPTIntercept Pharmaceuticals, Inc.
-2.12%101.5318.7%$49.22m
SAGESAGE Therapeutics, Inc.
-3.66%120.259.6%$48.34m
UTHRUnited Therapeutics Corporation
0.25%123.4214.4%$36.83m
CTLTCatalent Inc
0.22%41.562.4%$33.68m
ICLRICON Plc
-0.52%144.164.1%$32.82m
AERIAerie Pharmaceuticals, Inc.
1.57%56.246.9%$27.13m
PCRXPacira Pharmaceuticals, Inc.
2.67%45.3210.6%$26.60m
PTLAPortola Pharmaceuticals, Inc.
-2.83%23.377.7%$26.18m

Company Profile

MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.